[1. Harake D, Franco VI, Henkel JM, Miller TL, Lipshultz SE. Cardiotoxicity in childhood cancer survivors: strategies for prevention and management. Future Cardiol. 2012;8(4):647-70. DOI: 10.2217/fca.12.4410.2217/fca.12.44]Search in Google Scholar
[2. Gillespie HS, McGann CJ, Wilson BD. Noninvasive diagnosis of chemotherapy related cardiotoxicity. Curr Cardio Rev. 2011; 7: 234-44. DOI: 10.2174/15734031179996067210.2174/157340311799960672]Search in Google Scholar
[3. Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014; 64(9): 938-45. DOI: 10.1016/j. jacc.2014.06.1167]Search in Google Scholar
[4. Tian S, Hirshfield KM, Jabbour SK, Toppmeyer D, Haffty BG, Khan AJ, Goyal S. Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients. Front Oncol. 2014;4:277. DOI: 10.3389/fonc.2014.0027710.3389/fonc.2014.00277]Search in Google Scholar
[5. Christenson ES, James T, Agrawal V, Park BH. Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. Clin Biochem. 2015;48(4-5):223-35. DOI: 10.1016/j.clinbiochem.2014.10.01310.1016/j.clinbiochem.2014.10.013]Search in Google Scholar
[6. Van der Pal HJ, van Dalen EC, van Delden E, van Dijk IW, Kok WE, Geskus RB et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol. 2012;30(13):1429-37. DOI: 10.1200/ JCO.2010.33.473010.1200/JCO.2010.33.4730]Search in Google Scholar
[7. Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes- a report forn the Children’s Oncology Group. J Clin Oncol. 2012; 30(13):1415-21. DOI: 10.1200/JCO.2011.34.898710.1200/JCO.2011.34.8987]Search in Google Scholar
[8. Wallace KB, Hausner E, Herman E, Holt GD, MacGregor JT, Metz AL et al. Serum troponins as biomarkers of drug-induced cardiac toxicity. Toxicol Pathol. 2014;32(1):106-21. DOI: 10.1080/0192623049026130210.1080/01926230490261302]Search in Google Scholar
[9. Azzazy HM, Persers MM, Christenson RH. Unbound free fatty acid-binding protein: diagnosis assays and clinical applications. Clin Chem. 2006;52(1):19-29. DOI: 10.1373/clinchem.2005.05614310.1373/clinchem.2005.056143]Search in Google Scholar
[10. Liao J, Chan CP, Cheung YC, Lu JH, Luo Y, Cautherley GW et al. Human heart-type fatty acid-binding protein for on-site diagnosis of early acute myocardial infarction. Int J Cardiol. 2009;133(3):420-3. DOI: 10.1016/j. ijcard.2008.01.049]Search in Google Scholar
[11. Jacobs LH, van Borren M, Gemen E, van Eck M, van Son B, Glatz JF, et al. Rapidly rule out acute myocardial infarction by combining copeptin and heat-type fatty acid-binding protein with cardiac troponin. Ann Clin Biochem. 2015;52(5):550-61. DOI: 10.1177/000456321557818910.1177/0004563215578189]Search in Google Scholar
[12. Glatz JF, van der Vusse GJ, Simoons ML, Kragten JA, van Dieijen-Visser MP, Hermens WT. Fatty acid-binding protein and the early detection of acute myocardial infarction. Clin Chim Acta. 1998;272(1):87-92. DOI: 10.1016/S0009-8981(97)00255-6 10.1016/S0009-8981(97)00255-6]Search in Google Scholar